BillionToOne

Precision molecular diagnostics company (NASDAQ: BLLN) that quantifies biology at the single-molecule level to detect and measure DNA molecules. Its molecular counting platform underpins UNITY Complete, a non-invasive prenatal screen assessing fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw, and the Northstar liquid biopsy franchise: Northstar Select reports tumor mutations from blood, while Northstar Response is a methylation-based assay quantifying cancer burden in real time without a tissue biopsy. Incorporated in 2016 and publicly listed in November 2025, the company grew revenue more than 60% year over year in Q2 2026.